Although SGLT-2 inhibitors have demonstrated significant efficacy and broad potential in non-diabetic CKD patients, their use requires careful management of potential side effects, such as urinary tract infections, hypotension, and diabetic ketoacidosis. The gene discussed is SLC5A2; the disease is urinary tract infection.